Most cancer patients receive radio- and/or chemotherapy that causes DNA damage, which blocks DNA replication. Normal and tumor cells respond to DNA damage and associated replication stress by activating DNA repair, cell cycle arrest (checkpoint) systems, and when damage is severe, programmed death pathways, collectively termed the DNA damage response (DDR). DDR proteins play crucial roles in tumor suppression and genome stabilization (cancer etiology) as well as tumor response to radio- and chemotherapy (cancer treatment). DDR pathways determine cell fates in response to DNA damage, including cell survival, genome stability, and cell death/permanent growth arrest via apoptosis, autophagy, necrosis, senescence, or mitotic catastrophe. Cells are particularly vulnerable to DNA damage during S phase because most DNA lesions stall replication forks, causing replication stress. This proposal focuses on several proteins with roles in DNA repair, checkpoint activation, and recovery from replication stress. Metnase and DNA-PK were both initially characterized for their roles in DNA double-strand break (DSB) repair by non-homologous end joining (NHEJ). Recent studies demonstrate that Metnase and DNA-PK (along with replication protein A (RPA), ATM/ATR, Chk1, and others) also function in checkpoint activation and replication stress recovery. The replication checkpoint prevents new origin firing and stabilizes stalled replication forks to prevent fork collapse, allowing time for repair and for restart. Persistent replication stress can lead to fork collapse, producing one-ended DSBs marked by phosphorylated H2AX (?-H2AX). RPA accumulates on single-stranded DNA at stalled forks and the RPA32 subunit is phosphorylated at multiple sites by phosphoinositide 3-kinase-related protein kinases (PIKKs) DNA-PK, ATM and ATR, leading to Chk1 activation and replication arrest. Metnase also regulates Chk1 activation and replication arrest. Our central hypothesis is that Metnase, DNA-PK, and RPA operate within the DDR to influence cell fate after genotoxic stress, including cell survival, genome stability, and death pathway activation. We will determine roles of Metnase (Aim 1) and PIKK phosphorylation of RPA (Aim 2) in replication stress responses including replication arrest, fork restart, genome stability, cell survival and cell death by apoptosis.
In Aim 3 we will define epistatic relationships between Metnase and PIKK/RPA pathways, and test novel combinations of replication stress agents plus DDR inhibitors to enhance killing of breast, lung, pancreatic, colon, head and neck, and leukemic tumor cells. A better understanding of how DDR factors regulate cell fate decisions will drive the development of novel cancer therapies to improve local tumor control, and reduce the risk of therapy-induced tumor progression and secondary tumor induction.

Public Health Relevance

Most cancer patients receive radiotherapy and/or chemotherapy that damages DNA and blocks DNA replication. Normal and tumor cells respond to these threats by activating DNA repair pathways and arresting cell cycle progression, collectively called the DNA damage response network. This project is focused on understanding how DNA damage response proteins determine cell fate after chemotherapy. These studies will help us design more effective therapeutic strategies that increase local tumor control, and minimize therapy- induced tumor progression and secondary tumor induction.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01GM084020-06
Application #
8725682
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Willis, Kristine Amalee
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Public Health & Prev Medicine
Type
Schools of Veterinary Medicine
DUNS #
City
Fort Collins
State
CO
Country
United States
Zip Code
80521
Chun, Changzoon; Wu, Yuehan; Lee, Suk-Hee et al. (2016) The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis. Cell Cycle 15:957-62
Lee, Younghyun; Li, Huizi Keiko; Masaoka, Aya et al. (2016) The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining. Radiother Oncol 121:162-168
Wu, Yuehan; Lee, Suk-Hee; Williamson, Elizabeth A et al. (2015) EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair. PLoS Genet 11:e1005675
Nickoloff, Jac A (2015) Photon, light ion, and heavy ion cancer radiotherapy: paths from physics and biology to clinical practice. Ann Transl Med 3:336
Allen, Christopher P; Tinganelli, Walter; Sharma, Neelam et al. (2015) DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation. Front Oncol 5:260
Williamson, Elizabeth A; Wu, Yuehan; Singh, Sudha et al. (2014) The DNA repair component Metnase regulates Chk1 stability. Cell Div 9:1
Wei, Hong-Jian; Nickoloff, Jac A; Chen, Wei-Hong et al. (2014) FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget 5:9514-29
Ashley, Amanda K; Shrivastav, Meena; Nie, Jingyi et al. (2014) DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe. DNA Repair (Amst) 21:131-9
Kim, Hyun-Suk; Chen, Qiujia; Kim, Sung-Kyung et al. (2014) The DDN catalytic motif is required for Metnase functions in non-homologous end joining (NHEJ) repair and replication restart. J Biol Chem 289:10930-8
Nickoloff, Jac A (2013) Assaying DNA double-strand break induction and repair as fast as a speeding comet. Cell Cycle 12:1335-6

Showing the most recent 10 out of 24 publications